ProCE Banner Events

Share

Clinical Insights and Guidance on New Evidence and the Expanding Treatment Options for Hemophilia


Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with hemophilia.

Time and location

Wednesday, February 08, 2023

3:30 PM - 4:30 PM Pacific Time (PT)

Virtual

Agenda

Advances in Factor Replacement Therapy

  • Goals of hemophilia treatment
  • Current data on the safety and efficacy of approved clotting factor replacement
  • Managing adherence to optimize therapeutic benefit
  • Future directions in factor replacement therapy

Improving Outcomes With Nonfactor Therapy for Hemophilia

  • FVIII mimetic antibodies
  • Investigational mimetic antibodies

Emerging Therapies Targeting Hemostatic Balance

  • Future directions in nonfactor therapy in hemophilia A and B
    • Rebalancers of hemostasis: anti-thrombin and inhibitors of coagulation inhibitors

Advancing Toward a Cure: Gene Therapy

  • Mechanisms of action and rationale for gene therapy in hemophilia
  • Ongoing clinical trials in gene therapy: hemophilia A & B
  • Implementation of gene therapy into clinical practice

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in using novel therapeutic options for patients with hemophilia A and B.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized hemophilia A and B prophylactic strategies that optimize adherence and clinical outcomes
  • Apply recent safety and efficacy data for newer factor replacement therapies in hemophilia A and B to clinical practice
  • Integrate the most recent data on currently available and emerging nonfactor prophylaxis into clinical practice for patients with hemophilia A and B
  • Discuss with patients the mechanisms of action, available data, along with benefits and potential risks of emerging gene therapies in hemophilia A and B care
  • Identify patients with hemophilia A or B who may be eligible for enrollment on a clinical trial

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-247-L01-P.

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from:

Novo Nordisk
Sanofi Genzyme

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.